Dyne Therapeutics to present one-year Phase 1/2 ACHIEVE data for DM1 drug DYNE-101 at upcoming meetings

• Dyne Therapeutics set presentations of additional one-year Phase 1/2 ACHIEVE data for z-basivarsen in myotonic dystrophy type 1.
• Results will be presented at World Muscle Society and AANEM meetings starting Sept. 29, 2026; data have not yet been presented.
• Updates are expected to show sustained functional improvement versus a matched natural history cohort, alongside updated safety findings.
• Baseline hand-function measure from the blinded registrational expansion cohort will be disclosed; topline data remain scheduled for Q1 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dyne Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609080751PRIMZONEFULLFEED9822763) on September 08, 2026, and is solely responsible for the information contained therein.